Science: HK2 - A Major Driver of Cancer
VDA-1102 VDAC/HK2 MOA
HKS N-terminal-helix flips out of place to allow VDAC's N-terminal-helix to replace it, thus binding the two proteins.
VDA-1102 Inhibits Cancer Proliferation
VDA-1102 demonstrated strong inhibition of cancer growth across multiple indications.
70% of a panel with 57 cancer models (2019-2021)
Threshold <2uM; Colony forming assay in 57 patient-derived tumors and cancer cell lines conducted at Oncotest GmbH, a division of Charles River Labs.
Pipeline
Vidac has built a portfolio of novel product candidates that target significant unmet medical needs in oncology and dermatology.